PPAR agonists in PBC: Where do we go from here? Or how to choose between the new and the old
{{output}}
The recent phase 3 trials of peroxisome proliferator-activated receptor (PPAR) agonists in primary biliary cholangitis (PBC) patients with incomplete response to ursodeoxycholic acid (UDCA) demonstrated very promising short-term biochemical responses. However,... ...
